Jinxin Fertility Group Limited has announced key operating data for the fourth quarter of 2025. According to the company, the number of in vitro fertilization $(IVF)$ treatment cycles increased in the fourth quarter of 2025 compared to the third quarter of 2025, following ongoing operational optimization initiatives. The company also reported that its business in Greater China for 2025 demonstrated resilience, with the number of IVF treatment cycles for the full year of 2025 showing only a 0.4% decrease compared to the full year of 2024. This comes after the company experienced an 8.0% decrease previously. The update is based on preliminary internal assessment and unaudited figures. The company advises shareholders and potential investors to exercise caution when dealing in its shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jinxin Fertility Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260106-11980378), on January 05, 2026, and is solely responsible for the information contained therein.